跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies
Po Hong Liu
,
Teh Ia Huo
, Rebecca A. Miksad
*
*
此作品的通信作者
藥理學研究所
研究成果
:
Review article
›
同行評審
114
引文 斯高帕斯（Scopus）
總覽
指紋
指紋
深入研究「Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Tumor
100%
Management Strategy
100%
Hepatocellular Carcinoma
100%
Best Management Practices
100%
Portal Vein
100%
Portal Vein Tumor Thrombus
100%
Sorafenib
45%
Blood Flow
18%
Complex Disease
18%
Hepatocellular Carcinoma Patients
18%
Disease Entity
18%
United States
9%
Potential Treatments
9%
Clinical Trials
9%
Treatment Efficacy
9%
Trunk
9%
Advanced Stage
9%
Narrative Review
9%
Overall Survival
9%
Treatment Options
9%
Targeted Therapy
9%
Liver Function
9%
Marginal Benefit
9%
Blood Vessels
9%
Heterogeneous Disease
9%
Standard of Care
9%
Recurrence Rate
9%
Function Requirement
9%
Recurrence Risk
9%
Aggressive Disease
9%
Immune Therapy
9%
Tumor Location
9%
Disease Course
9%
Nuclear Medicine
9%
Liver Reserve Function
9%
Advanced Hepatocellular Carcinoma
9%
Barcelona Clinic Liver Cancer
9%
Multidisciplinary Management
9%
Median Overall Survival
9%
Second-line Therapy
9%
Nivolumab
9%
Hepatic Function
9%
Regorafenib
9%
Lenvatinib
9%
Tumor Risk
9%
Limited Treatment Options
9%
Cabozantinib
9%
Interventional Radiology
9%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Hepatic Portal Vein
100%
Vascular Tissue Neoplasm
100%
Tumor Thrombus
91%
Sorafenib
41%
Liver Function
25%
Blood Flow
16%
Overall Survival
16%
Diseases
16%
Immunotherapy
8%
Recurrent Disease
8%
Disease Course
8%
Clinical Trial
8%
Neoplasm
8%
Cancer Staging
8%
Targeted Therapy
8%
Prospective Study
8%
Liver Cancer
8%
Vascular Bundle
8%
Recurrence Risk
8%
Immunity
8%
Nivolumab
8%
Lenvatinib
8%
Interventional Radiology
8%
Regorafenib
8%
Cabozantinib
8%
Nuclear Medicine
8%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Vascular Tumor
100%
Tumor Thrombus
91%
Sorafenib
41%
Overall Survival
16%
Diseases
16%
Immunotherapy
8%
Recurrent Disease
8%
Clinical Trial
8%
Neoplasm
8%
Cancer Staging
8%
Prospective Study
8%
Liver Cancer
8%
Disease Course
8%
Recurrence Risk
8%
Nivolumab
8%
Regorafenib
8%
Lenvatinib
8%
Cabozantinib
8%